title: Evaluation of exclusive use of ivermectin vs alternation of antiparasitic compounds for control of internal parasites of horses.
abstract: A study for about a 30-month period was done to compare strongyle control programs, using per os treatments of ivermectin (IVE) paste exclusively or alternation of 4 antiparasitic paste compounds: IVE, oxfendazole (OFZ), oxibendazole (OBZ), or pyrantel pamoate (PRT). Every 8 weeks, 1 group of horses (barn C; n = 14 to 16) was given IVE paste exclusively, and a second group (barn E; n = 16) was given the 4 antiparasitic pastes on an alternating schedule. Worm eggs and larvae per gram of feces (epg and lpg, respectively) values were determined every 2 weeks during the investigation. This study in grazing horses (mares and fillies), naturally infected with internal parasites, was conducted during the period between Oct 22, 1987 and Feb 8, 1990, with an additional observation on Mar 28, 1990. For barn-C horses, treated exclusively with IVE (200 micrograms/kg of body weight) 14 times, 2-week posttreatment mean strongyle epg and lpg (small strongyle) values were reduced 99 to 100%. Mean strongyle epg and lpg (small strongyle) values for each 2-week sample period remained low (less than 20) throughout the study period, except for 1 moderate transient increase in July 1988. For the entire study period, the aggregate mean strongyle epg value was 12 and the lpg value was 6. Two-week posttreatment mean strongyle epg and lpg (small strongyle) values for barn-E horses, treated alternately with therapeutic (approx) dosage of IVE (200 micrograms/kg; 4 times), OFZ (10 mg/kg; 5 times), OBZ (10 mg/kg; 4 times), or PRT (6.6 mg base/kg; 2 times), varied within and between compounds.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Veterinary Science, University of Kentucky, Lexington 40546-0099.
authors.forename: E T
authors.initials: ET
authors.lastname: Lyons
authors.forename: J H
authors.initials: JH
authors.lastname: Drudge
authors.forename: S C
authors.initials: SC
authors.lastname: Tolliver
authors.forename: D E
authors.initials: DE
authors.lastname: Granstrom
authors.forename: S
authors.initials: S
authors.lastname: Stamper
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005243:Feces / Q000469:parasitology; D005260:Female; D006734:Horse Diseases / Q000517:prevention & control*; D006736:Horses; D007411:Intestinal Diseases, Parasitic / Q000517:prevention & control / Q000662:veterinary*; D007420:Intestine, Large / Q000469:parasitology; D007559:Ivermectin / Q000008:administration & dosage / Q000627:therapeutic use*; D007814:Larva / Q000302:isolation & purification; D009824:Ointments; D010270:Parasite Egg Count / Q000662:veterinary; D011716:Pyrantel Pamoate / Q000008:administration & dosage / Q000627:therapeutic use; D013319:Strongyle Infections, Equine / Q000517:prevention & control*; D013320:Strongyloidea / Q000302:isolation & purification
chemical_list: D000871:Anthelmintics; D001562:Benzimidazoles; D009824:Ointments; C011321:oxibendazole; D007559:Ivermectin; D011716:Pyrantel Pamoate; C011030:oxfendazole